Free Trial

Adagene (ADAG) Competitors

Adagene logo
$1.66 +0.10 (+6.41%)
Closing price 05/21/2025 03:57 PM Eastern
Extended Trading
$1.66 0.00 (0.00%)
As of 05/21/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADAG vs. ARCT, HRTX, SEPN, BNTC, FULC, ATYR, ATAI, ACB, AQST, and CMPX

Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), Benitec Biopharma (BNTC), Fulcrum Therapeutics (FULC), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.

Adagene vs.

Arcturus Therapeutics (NASDAQ:ARCT) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Adagene has lower revenue, but higher earnings than Arcturus Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$131.27M2.51-$29.73M-$2.53-4.80
Adagene$103.20K757.75-$18.95MN/AN/A

Arcturus Therapeutics presently has a consensus target price of $57.80, suggesting a potential upside of 375.72%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 381.93%. Given Adagene's higher possible upside, analysts plainly believe Adagene is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Adagene
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Adagene has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Adagene's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-36.39% -22.39% -14.81%
Adagene N/A N/A N/A

In the previous week, Arcturus Therapeutics had 14 more articles in the media than Adagene. MarketBeat recorded 14 mentions for Arcturus Therapeutics and 0 mentions for Adagene. Arcturus Therapeutics' average media sentiment score of 0.60 beat Adagene's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Arcturus Therapeutics Positive
Adagene Neutral

Arcturus Therapeutics received 427 more outperform votes than Adagene when rated by MarketBeat users. However, 79.31% of users gave Adagene an outperform vote while only 66.47% of users gave Arcturus Therapeutics an outperform vote.

CompanyUnderperformOutperform
Arcturus TherapeuticsOutperform Votes
450
66.47%
Underperform Votes
227
33.53%
AdageneOutperform Votes
23
79.31%
Underperform Votes
6
20.69%

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arcturus Therapeutics has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Adagene has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Adagene on 9 of the 17 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAG vs. The Competition

MetricAdagenePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$78.20M$6.52B$5.37B$8.39B
Dividend YieldN/A2.65%5.22%4.10%
P/E RatioN/A8.9226.7719.71
Price / Sales757.75253.80393.17117.39
Price / CashN/A65.8538.2534.62
Price / Book1.036.466.794.50
Net Income-$18.95M$143.98M$3.23B$248.18M
7 Day Performance-6.21%2.03%1.53%0.20%
1 Month Performance14.48%4.11%10.06%12.37%
1 Year Performance-36.40%-2.87%16.74%7.04%

Adagene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAG
Adagene
2.3111 of 5 stars
$1.66
+6.4%
$8.00
+381.9%
-35.9%$78.20M$103,204.000.00260Positive News
Gap Up
ARCT
Arcturus Therapeutics
2.9267 of 5 stars
$11.59
+5.6%
$59.20
+410.8%
-59.3%$314.33M$138.39M-5.22180
HRTX
Heron Therapeutics
3.8615 of 5 stars
$2.05
-2.8%
$5.50
+168.3%
-45.3%$312.76M$148.52M-11.39300Positive News
SEPN
Septerna
2.0583 of 5 stars
$6.98
+4.3%
$33.00
+372.8%
N/A$310.72M$1.08M0.00N/AEarnings Report
Analyst Revision
BNTC
Benitec Biopharma
2.4171 of 5 stars
$13.14
-3.6%
$24.71
+88.1%
+42.3%$308.15M$80,000.00-8.7020News Coverage
Analyst Forecast
Analyst Revision
FULC
Fulcrum Therapeutics
0.7844 of 5 stars
$5.68
+5.8%
$8.63
+51.8%
-18.2%$306.60M$80M-18.32100
ATYR
Atyr PHARMA
2.8106 of 5 stars
$3.24
-1.2%
$18.60
+474.1%
N/A$288.37M$235,000.00-3.4553Analyst Forecast
ATAI
Atai Life Sciences
2.3356 of 5 stars
$1.44
+3.6%
$10.50
+629.2%
+13.7%$287.71M$308,000.00-1.7880News Coverage
Analyst Forecast
Gap Down
ACB
Aurora Cannabis
0.6189 of 5 stars
$5.06
+4.3%
N/A-26.8%$284.44M$320.81M101.221,340
AQST
Aquestive Therapeutics
1.3053 of 5 stars
$2.85
+2.2%
$10.67
+274.3%
-28.6%$283.07M$57.56M-6.33160Analyst Revision
Gap Down
CMPX
Compass Therapeutics
3.678 of 5 stars
$2.01
+10.4%
$13.13
+553.0%
+28.8%$277.95M$850,000.00-5.4320

Related Companies and Tools


This page (NASDAQ:ADAG) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners